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Abstract
Efficient hematopoietic stem cell (HSC) homing is important for hematopoietic cell 
transplantation (HCT), especially when HSC numbers are limited, as with the use of cord blood 
(CB). In a screen of small molecule compounds, we identified glucocorticoid hormone signaling 
as an activator of CXCR4 expression in human CB HSCs and hematopoietic progenitor cells 
(HPCs). Short-term glucocorticoid (GC) pretreatment of human CB HSC/HPCs promoted SDF-1/
CXCR4 mediated chemotaxis, homing, and long-term engraftment when transplanted into primary 
and secondary NSG mice. Mechanistically, activated glucocorticoid receptor binds directly to a 
glucocorticoid response element (GRE) in the CXCR4 promoter and recruits the SRC1/p300 
complex to promote H4K5 and H4K16 histone acetylation, facilitating transcription of CXCR4. 
These results suggest a new and readily available means to enhance the clinical efficacy of CB 
HCT.
Hematopoietic stem cells (HSCs), which give rise to all blood cell types, are essential cells 
for successful hematopoietic cell transplantation (HCT)1. Cord blood (CB) is an increasingly 
used source of HSC for HCT2, which is used to treat patients with malignant and non-
malignant hematological disorders. One limitation to greater usage of CB for HCT is that 
HSCs are present in only limited numbers in a single unit of CB3. While ex vivo expansion 
of HSCs is currently being assessed for enhancement of CB HCT3–5, another means to 
enhance single CB unit HCT is to enhance the homing, and thus the engraftment efficiency 
of HSCs.
Intravenously infused HSCs traffic to bone marrow (BM) and implant in 
microenvironmental niches, where they are nurtured for self-renewal and differentiation6. 
The SDF-1/CXCR4 chemotactic axis is a major pathway directing the migration and homing 
of HSC from peripheral blood to BM niches7,8. By modulating the interplay between SDF-1 
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and CXCR4, HSC homing efficiency can be improved. For example, DPP4 inhibition blocks 
proteolytic inactivation of SDF-1 and enhances engraftment of HSCs9, treatment with PGE2 
or valporic acid facilitates HSC chemotaxis towards SDF-1 gradients by upregulating 
CXCR4 surface expression10–12, and mild heat exposure promotes incorporation of CXCR4 
into lipid rafts enhancing HSC chemotaxis and engraftment13. However, there is still a need 
for other methods to enhance homing and engraftment of HSCs.
Small synthetic molecules have been evaluated for their effects on HSC function3–5. To 
identify compounds that might be useful for increasing HSC homing efficiency, we 
performed a small scale compound screen for molecules that can upregulate surface 
expression of CXCR4 on human CB CD34+ cells. From a nuclear hormone ligand library 
including 74 chemical compounds (Supplementary Table 1), we found that treatment of CB 
CD34+ cells for 16 hours with dexamethasone (Dex), a synthetic glucocorticoid, greatly 
promoted cell surface expression of CXCR4 (Fig. 1a). Expression of CXCR4 on CB CD34+ 
cells was also increased after treating cells with other glucocorticoids (which were not 
present in the library) including Flonase (Fluticasone propionate), cortisol (Hydrocortisone), 
and Medrol (Methylprednisolone) (Fig. 1b). We focused on Flonase, which of these 
compounds forms the most stable activated complex with glucocorticoid receptor (GR)14. 
Flonase treatment enhanced CXCR4 expression at concentrations as low as 10 nM 
(Supplementary Fig. 1a). Flow cytometry and confocal imaging analysis demonstrated a 
dramatic increase in surface CXCR4 expression on CB CD34+ cells treated with Flonase, 
compared to the vehicle control (Fig. 1c,d and Supplementary Fig. 1b). Flonase also 
enhanced CXCR4 surface expression on HSCs (CD34+CD38−CD45RA−CD49f+CD90+), 
multipotential progenitors (MPPs, CD34+CD38−CD45RA−CD49f−CD90−), and 
CD34+CD38− cells (Fig. 1e and Supplementary Fig. 1c,d).
Next, we assessed if GCs can enhance chemotaxis of HSCs and HPCs towards SDF-1. 
Flonase pre-treatment greatly enhanced chemotaxis of CB CD34+ cells to graded doses of 
SDF-1 (Fig. 1f), as well as chemotaxis to SDF-1 of CD34+CD38− cells, HSCs and MPPs 
(Fig. 1g and Supplementary Fig. 1e,f). Chemotaxis of CB CD34+ cells to SDF-1 was also 
enhanced by treating the cells with Dex, cortisol or Medrol (Supplementary Fig. 1g). The 
glucocorticoid receptor (GR) was expressed most highly in human CB HSCs as compared to 
other CB cell types tested (Supplementary Fig. 1h,i); moreover, expression of GR on CB 
HSC, CD34+ or CD34+CD38− cells was higher than on CB CD34− cells (Supplementary 
Fig. 1h,i), suggesting that GC signaling may be of significance for the physiological 
functioning of HSCs and HPCs.
To evaluate whether facilitated chemotaxis of CB HSCs and HPCs towards SDF-1 by GC 
pretreatment depends on CXCR4, we used AMD3100, a CXCR4 antagonist15. Treatment 
with AMD3100 fully blocked the effects of Flonase on chemotaxis of CB CD34+ cells to 
SDF-1 (Fig. 1h), demonstrating that GC acts through the SDF-1/CXCR4 axis. Since 
activation of GR increased surface expression of CXCR4 on CB HSCs and HPCs and 
enhanced SDF-1/CXCR4 mediated chemotaxis, we next evaluated whether inactivation of 
GR would have opposite effects. RU486, a widely used GR antagonist, did not change the 
basal level of CXCR4 surface expression of CB CD34+ cells, and had no effect on the 
chemotaxis of CB CD34+ cells towards SDF-1 (Supplementary Fig. 1j,k). However, RU486 
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neutralized the increased surface expression of CXCR4 and the enhanced chemotaxis 
induced by GC (Supplementary Fig. 1j,k). This suggests that GR signaling, while 
dispensable for basal levels of CXCR4 expression, was important for increased surface 
expression of CXCR4 on CB HSCs and HPCs, thus facilitating their response to SDF-1 
induced chemotaxis.
We next tested if GC treatment enhances in vivo homing. We treated human CB CD34+ cells 
with vehicle or Flonase for 16 hours and evaluated homing in sublethally irradiated NSG 
mice. Flonase, cortisol and Dex treatment significantly enhanced the homing efficiency of 
CB CD34+ cells by 4.4-fold, 2.5-fold and 3.0-fold respectively (Fig. 1i and Supplementary 
Fig. 2a,b). To assess the long-term reconstituting ability of GC-pretreated human CB CD34+ 
cells, we performed limiting dilution analysis to calculate the frequency of SCID 
repopulating cells (SRC), a measure of functional human HSCs1. Flonase-treated CB cells 
demonstrated significantly increased engraftment in primary NSG recipients compared with 
that of the vehicle control group, with increased human myeloid, B cell and T cell 
chimerism (Fig. 1j,k and Supplementary Fig. 2c–h). A Poisson distribution analysis revealed 
an SRC frequency of 1/4162 for vehicle-treated CB CD34+ cells and an enhanced SRC 
frequency of 1/611 for Flonase-treated CB CD34+ cells, indicating the presence of 240 
SRCs and 1637 SRCs in vehicle- and Flonase-treated cells, respectively (Fig. 1l,m and 
Supplementary Table 2); A second Poisson distribution analysis from another independent 
experiment revealed an SRC frequency of 1/7344 for vehicle-treated CB CD34+ cells and an 
enhanced SRC frequency of 1/1576 for Flonase-treated CB CD34+ cells, indicating the 
presence of 136 SRCs and 635 SRCs in vehicle- and Flonase-treated cells, respectively 
(Supplementary Fig. 2i,j and Supplementary Table 3). Enhanced engraftment of Flonase-
treated as compared to vehicle-treated cells was also apparent in transplanted secondary 
recipients (Fig. 1n), demonstrating effects of Flonase treatment on a long-term repopulating 
and self-renewing HSC population. Thus, short-term glucocorticoid treatment of human CB 
HSCs and HPCs enhances their homing and long-term engraftment.
Mechanistically, we hypothesized that GC might increase CXCR4 expression in human CB 
CD34+ cells via effects on CXCR4 transcription. Upon activation by agonists, GR 
translocates into the nucleus and forms a homodimer that regulates transcription by binding 
to glucocorticoid response elements (GREs) in the promoter region of target genes16. We 
found that GC (Flonase, cortisol, Dex) pretreatment significantly increased CXCR4 mRNA 
levels in human CB CD34+ cells, as assessed by quantitative real-time PCR analysis (Fig. 
2a). CXCR4 protein levels were also upregulated in Flonase-, cortisol- or Dex-treated 
human CB CD34+ cells compared to control cells (Fig. 2b,c). We searched for the consensus 
GR binding sequence AGAACAnnnTGTNCN17 and found a putative glucocorticoid 
response element (GRE) AGAACATTCTGTGCA in the human CXCR4 promoter region 
(from −1,662 bp to −1,648 bp upstream of the transcription start site). Chromatin 
immunoprecipitation analysis indicated enrichment for the GR was in this region of the 
CXCR4 promoter upon GC treatment (Fig. 2d and Supplementary Fig. 3a). Using a dual 
luciferase reporter assay system to examine whether GC administration directly enhances 
promoter activity of CXCR4, we found that the luciferase signal was significantly enhanced 
by Flonase treatment, and that this effect was abrogated by disruption of the GRE in the 
CXCR4 promoter (Fig. 2e).
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Next, we assessed how GR might activate transcription of CXCR4 upon binding to the GRE 
in the promoter region. Nuclear hormone receptors (NRs) can directly or indirectly associate 
with coactivators, including SRC1 (steroid receptor coactivator-1), CBP (CREB binding 
protein) and p300 (E1A binding protein p300), which have histone acetyltransferase activity 
and acetylate histones associated with target gene promoters18,19. Accordingly, we 
investigated histone acetylation levels in the CXCR4 promoter region and found that, 
compared to the vehicle control, Flonase treatment dramatically enhanced the acetylation 
levels of histone H4 on lysines 5 and 16 (H4K5 and H4K16) (Fig. 2f,g), whereas the 
acetylation levels of histone H3 (H3K9 and H3K14) were unchanged (Supplementary Fig. 
3b). Flonase treatment did not affect acetylation levels of total H4 (Supplementary Fig. 3c), 
suggesting that GR signaling specifically targets CXCR4. The interaction between GR and 
SRC1/p300 complex was increased by Flonase treatment, as assessed by co-
immunoprecipitation analysis (Fig. 2h). Notably, treatment of CB CD34+ cells with c646, a 
histone acetyltransferase p300 inhibitor, or knockdown of SRC1 or p300, suppressed the 
effects of Flonase, cortisol and Dex on CXCR4 expression (Fig. 2i and Supplementary Fig. 
3d,e) and suppressed the effects of Flonase pre-treatment on SDF-1/CXCR4 mediated 
chemotaxis (Supplementary Fig. 3f). Knockdown of CBP did not suppress Flonase-induced 
cell surface expression of CXCR4 (Supplementary Fig. 3d,e), suggesting that p300 but not 
CBP is involved in the selective histone acetylation induced by GC. Treatment with the p300 
inhibitor also suppressed the enhanced homing of Flonase-treated CB CD34+ cells (Fig. 2j). 
These data demonstrate that the increased homing efficiency resulting from activation of GR 
signaling depends on enhanced histone acetylation at CXCR4.
Notably, we could not identify a consensus GRE in the mouse Cxcr4 promoter, and 
glucocorticoid treatment did not affect Cxcr4 mRNA levels or Cxcr4 surface expression of 
mouse hematopoietic stem and progenitor cells and did not affect their chemotaxis to SDF-1 
(Supplementary Fig. 3g–i).
Our findings show that upon GC treatment, activated GR binds to the GRE at the CXCR4 
promoter region, transcriptionally up-regulating CXCR4 expression and thereby enhancing 
the homing efficiency and engraftment capability of human CB CD34+ cells (Fig. 2k).
Histone acetylation is one of the major epigenetic chromatin remodeling pathways that 
regulate gene transcription. Acetylation, which targets the amino terminal regions of core 
histones and results in chromatin decondensation that prevents chromatin from forming 
higher-order structures, allows access to transcription factors or regulators20. Valporic acid, a 
histone deacetylase (HDAC) inhibitor, upregulates expression of CXCR4 and enhances 
SDF-1/CXCR4 axis-mediated chemotaxis11,12. However, direct modulation of HDAC 
activity may lead to changes in the expression profiles of many target genes, which could 
potentially result in detrimental effects.
Our studies demonstrate that glucocorticoid-bound GR recruits the SRC1/p300 
acetyltransferase complex to the CXCR4 promoter in CB CD34+ cells. Consistent with the 
notion that transcriptional regulation by GR is promoter- and cell type-dependent, GC 
administration did not increase global acetylation levels of H4, but specifically enhanced 
acetylation of H4K5 and H4K16 associated with the CXCR4 promoter. Many types of 
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synthetic GCs, including Flonase and dexamethasone, are widely used FDA-approved drugs 
for anti-inflammation and immunosuppressive therapy16. Our study indicates that GC pre-
treatment of cells has the potential to significantly enhance the engraftment of human CB 
HSC and HPC, designating GCs as promising drug candidates to facilitate clinical HCT.
METHODS
Mice
NSG (NOD.Cg-Prkdcscid IL2rgtm1Wjl/SzJ) mice (6–8 weeks old) were obtained from the In 
Vivo Therapeutics Core of the Indiana University School of Medicine (IUSM). All animal 
experiments followed protocols approved by The Institutional Animal Care and Use 
Committee of IUSM.
Isolation of CB CD34+ cells and cell culture
Mononuclear cells from normal human cord blood (CB) (CordUse, Orlando, FL, USA) were 
isolated by density gradient centrifugation with Ficoll-Paque Plus (GE Healthcare, 
Piscataway, NJ, USA). CD34+ cells were collected using an immunomagnetic selection kit 
(Miltenyi Biotec, Auburn, CA, USA). Briefly, mononuclear cells were resuspended in 
MACS buffer (0.5% BSA, 2mM EDTA in PBS, pH7.2). FcR blocking reagent (Miltenyi 
Biotec, #130-046-702) and CD34 microbeads (Miltenyi Biotec, #130-046-702) were added 
sequentially, and then the cells were incubated for 30 min in the refrigerator. The cells were 
washed with MACS buffer and centrifuged at 300 g for 10 min. The supernatant was 
aspirated and the cells were resuspended in 1 mL MACS buffer. Magnetic separation was 
performed with an appropriate MACS column (Miltenyi Biotec, #130-042-401). This 
procedure yields CD34+ cells with a purity of 90–98%. CB CD34+ cells were cultured in 
RPMI-1640 medium with 10% fetal bovine serum, 100 ng/mL stem cell factor (SCF) (R&D 
Systems, #7466-SC-010/CF), thrombopoietin (TPO) (R&D Systems, #288-TP-200/CF), and 
Fms-like tyrosine kinase 3 ligand (Ftl3L) (BioLegend, # 710802). For screening, 50,000 
CD34+ cells were cultured for 16 hours in the above medium in the presence of compounds 
(1 μM) from the Nuclear Receptor Ligand Library (Enzo Life Sciences, Farmingdale, NY, 
USA). For administration of glucocorticoids, Flonase (S1992, 1 μM), cortisol (S1696, 1 
μM), dexamethasone (S1322, 1 μM) or methylprednisolone (S1733, 1 μM) (Selleck 
Chemicals, Houston, TX, USA) was added to the medium and the cells were incubated for 
16 hours unless stated otherwise. Dimethyl sulfoxide (DMSO) (Sigma, # D2650) was used 
as vehicle control.
Mouse lineage negative bone marrow cell isolation and culture
Mouse bone marrow lineage cell depletion was performed using the mouse lineage cell 
depletion kit following the manufacturer’s protocol (Miltenyi Biotec, Auburn, CA, USA). 
Lineage negative mouse hematopoietic stem and progenitor cells were cultured in 
RPMI-1640 medium with 10% fetal bovine serum, 100 ng/mL mouse stem cell factor 
(mSCF) (R&D Systems, #455-MC-010), mouse thrombopoietin (mTPO) (R&D Systems, # 
488-TO-005/CF), and mouse Fms-like tyrosine kinase 3 ligand (mFtl3L) (BioLegend, 
#550706).
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Immunostaining and flow cytometry
Cells were collected by centrifuging at 300 g for 10 min, washed twice with cold PBS, 
resuspended in 200 μL PBS, and stained with fluorescence conjugated antibodies at 4 °C for 
30 min. The cells were washed with cold PBS and the samples were fixed with 1% 
formaldehyde. The samples were analyzed on an LSRII flow cytometer (BD Biosciences). 
For intracellular staining, after cell surface staining, the cells were fixed and permeabilized 
using the Cell Permeabilization Kit (Thermo Fisher, Florence, KY, USA). The cells were 
washed with cold PBS and then stained with primary antibodies at room temperature for 20 
min. APC or FITC-conjugated secondary antibodies were added and the cells were 
incubated for another 20 min. The cells were washed and fixed for flow cytometry analysis. 
The following antibodies from BD Bioscience (San Jose, CA, USA) were used for cell 
surface staining: CXCR4-APC (12G5), CD34-FITC (581), CD38-PE (HIT2), CD45RA-PE-
CF594 (HI100), CD90-PEcy7 (5E10) and CD49f-PerCPcy5.5 (GoH3), CD3-FITC 
(UCHT1), CD19-PE (HIB19), CD33-PEcy7 (WM53) and CD45-APC (HI30). The 
following antibodies were used for intracellular staining: anti-Glucocorticoid Receptor 
[BuGR2] (Abcam, Cambridge, MA, USA), anti-H4K5ac (9672) and anti-H4K16ac (13534) 
(Cell Signaling Technology, Beverly, MA, USA), anti-H3K9ac (#06-942) and anti-H3K14ac 
(#07-353) (Millipore, Kankakee, IL, USA). For mouse staining, the following antibodies 
were used: APC anti-mouse Cxcr4 (BD Bioscience, #558644), Brilliant Violet 421 anti-
mouse Lineage cocktail (Biolegend, #133311), PE/Cy7 anti-mouse Ly-6A/E (Sca-1) 
(Biolegend, #122513), APC anti-mouse CD117 (c-Kit) (Biolegend, #105811), FITC anti-
mouse CD48 (Biolegend, #103404), and PerCP/Cy5.5 anti-mouse CD150 (Biolegend, 
#115922).
Confocal imaging
Human CB CD34+ cells treated with vehicle or glucocorticoids were seeded on a Nunc glass 
bottom dish (Thermo Fisher Scientific, #150680) coated with poly-L-lysine. 
Immunostaining was performed using anti-CXCR4 [UMB2] (Abcam, Cambridge, MA, 
USA) and FITC labeled secondary antibodies. Cells were then washed, fixed and 
permeabilized. Samples were covered with mounting medium containing DAPI (Vector 
Laboratories). Fluorescence was examined using an Olympus FV-1000 confocal microscope.
Chemotaxis assay
Costar 24-well Transwell plates with 6.5 mm diameter inserts with 5.0 μm pores (Corning 
Inc, Corning, NY, USA) were used for the chemotaxis assay. 650 μL pre-warmed serum free 
IMDM medium containing SDF1 (50 ng/mL, unless otherwise indicated) was added to the 
lower chamber. Cells (1×105 cells/100 μL) were resuspended in IMDM with 0.5% bovine 
serum albumin (Sigma-Aldrich, Miamisburg, OH, USA). The cell suspension (100 μL) was 
placed in the upper chamber of the transwell. Transwell plates were placed in a 37 °C 
incubator with 5% CO2 and 95% humidity for 4 hours. The percentage migration was 
determined using flow cytometry with number of migrated cells in the lower chamber 
divided by number of cells placed in the upper chamber. A no-SDF-1 group was used to 
subtract background migration and served as a negative control group. For HSC migration 
assay, phenotypic HSC frequency was determined by surface staining and analyzed by flow 
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cytometry. CD34+CD38−CD45RA−CD90+CD49f+ cells were defined as HSCs. The 
migration percentage of human CB HSCs was calculated as the HSC 
(CD34+CD38−CD45RA−CD90+CD49f+) frequency among migrated CD34+ cells. For 
AMD3100 treatment, cells were pretreated with AMD3100 (Sigma, # 239820) for half hour 
before chemotaxis assay.
CD34+ CB cell homing assay
NSG mice were sublethally irradiated (with a single dose of 350 cGy, 137Cs) before 
transplantation. Glucocorticoid or vehicle treated CD34+ CB cells (500,000) were 
intravenously injected into each recipient NSG mouse. After 24 hours, mice were sacrificed 
and bone marrow mononuclear cells from a femur of each mouse were collected. 
Immunostaining with anti-human CD45 was performed. Samples were fixed in 1% 
formaldehyde buffer and analyzed by flow cytometry to determine the percentage of human 
CD45+ cells. Bone marrow cells from non-transplanted NSG mice were used as the negative 
control.
Limiting dilution analysis
The frequency of human SCID repopulating cells (SRCs) was analyzed by LDA as 
previously reported3. Increasing doses of vehicle or glucocorticoid treated CD34+ cells (500, 
2500, or 10,000 cells) were intravenously injected into NSG recipient mice that had been 
sublethally irradiated. Three or four months after transplantation, the mice were sacrificed 
and the percentage of human CD45+ cell, B cell, T cell and myeloid cell chimerism was 
determined by immunostaining and flow cytometry. For the long-term engraftment assay, 
5×106 bone marrow cells from the primary recipients of the 10,000 cell group were infused 
into secondary recipient mice. The HSC frequency was calculated using L-Calc software 
(Stem Cell Technologies Inc, Vancouver, BC, Canada) and plotted using ELDA software 
(bioinf.wehi.edu.au/software/elda/).
RNA extraction and Real-time PCR
RNA was extracted using the RNA Mini Kit following the manufacturer’s protocol 
(QIAGEN, #74106). Total RNA was reverse transcribed using the Invitrogen Superscript III 
kit. Quantitative real-time PCR reactions were performed using the SYBR Green PCR 
Master Mix (Thermo Fisher, Florence, KY, USA) and an Applied Biosystems 7500 Real-
Time PCR System. GAPDH was used as an internal control. The data are shown as relative 
mRNA level normalized to the level in vehicle control, which was set to 1. CXCR4 primers 
were: sense primer: 5′-TCTATGTTGGCGTCTGGATCC-3′, anti-sense primer: 5′-
CTTGGAGTGTGACAGCTTGG-3′. GAPDH primers were: sense primer: 5′-
TTCGTCATGGGTGTGAACCA-3′, anti-sense primer: 5′-
TGGCAGTGATGGCATGGACT-3′. For mouse Cxcr4 amplification, the following primers 
were used. mCxcr4 sense primer: 5′-GAGCATGACGGACAAGTACC -3′, anti-sense 
primer: 5′-TGGACAATAGCGAGGTACCG -3′. Actin sense primer: 5′-
CTTCTACAATGAGCTGCGTG-3′, anti-sense primer: 5′-
ATCACAATGCCTGTGGTACG-3′.
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Western blotting
Cells were lysed in RIPA buffer (25mM Tris-HCl pH 7.6, 150mM NaCl, 1% sodium 
deoxycholate, 0.1% SDS) with Halt TM Protease Inhibitor Cocktail (Thermo Fisher, 
Florence, KY, USA) on ice for 30 mis. Samples were centrifuged at 4 °C, 13,000 g for 15 
min. Collected supernatants and protein concentrations of the supernatants were quantified 
using the Protein Quantitation Kit (Abcam, Cambridge, MA, USA). Equal levels of total 
protein from different samples were subjected to SDS-PAGE analysis and signals were 
detected using corresponding primary and secondary antibodies. The following antibodies 
(1:1000 dilution) were used: anti-CXCR4 (Abcam, #ab181020) anti-SRC-1 (Cell Signaling 
Technology, 128E7, #2191); anti-Glucocorticoid Receptor (Cell Signaling Technology, 
D8H2, #3660); anti-p300 (Cell Signaling Technology, C-20, sc-585); anti-actin (Sigma, 
A3853).
Chromatin immunoprecipitation
The chromatin immunoprecipitation (ChIP) assay was performed using EZ-ChIP kit 
according to the manufacturer’s protocol (EMD Millipore, #17-371). CD34+ CB cells were 
cultured with vehicle or glucocorticoids for 16 hours. 1% formaldehyde was then added to 
the culture medium and the cells were incubated at 37 °C for 10 min. Cells were washed 
with cold PBS twice and then lysed in SDS lysis buffer with protease inhibitor for 10 min on 
ice. The cells were sonicated and then centrifuged at 4 °C, 13, 000 g for 15 min. The 
supernatant was diluted 1:10 with ChIP dilution buffer in the kit (EMD Millipore, #17-371). 
1% of the diluted sample from each group was used as the input control. Protein A agarose 
beads were added to the diluted sample and the sample was incubated at 4 °C with rotation 
for 30 min to eliminate the non-specific binding. The supernatant was collected and the 
beads were discarded. Control IgG or antibody was added to the samples which were 
incubated at 4 °C with rotation overnight. 60 μL Protein A agarose beads were added to each 
sample and the cells incubated at 4 °C with rotation for 1 hour. The samples were washed 
following the manufacturer’s instructions (EMD Millipore, #17-371). DNA-protein complex 
was eluted from the beads twice using elution buffer (1% SDS, 0.1M NaHCO3) in the kit 
(EMD Millipore, #17-371). Samples and the corresponding input were reverse cross-linked 
following the manufacturer’s protocol (EMD Millipore, #17-371). DNA was purified and 
subjected to real-time quantitative PCR analysis. Data are shown as the percentage of input. 
The primers used for CXCR4 qPCR were as follows: sense primer: 5′-
TTCCAGTGGCTGCATGTGTC-3′, anti-sense primer: 5′-
CAGACAATGTAACTCGCTCC-3′. The following antibodies were used for ChIP: anti-
Glucocorticoid Receptor [BuGR2] (Abcam, Cambridge, MA, USA), anti-H4K5ac (9672), 
and anti-H4K16ac (13534) (Cell Signaling Technology, Beverly, MA, USA), anti-H3K9ac 
(#06-942) and anti-H3K14ac (#07-353) (Millipore, Kankakee, IL, USA).
Co-immunoprecipitation
Cells were lysed in immunoprecipitation (IP) buffer (50 mM Tris-HCl pH 7.5, 150 mM 
NaCl, 1 mM EDTA, 1% Triton X-100 and protease inhibitor cocktail) on ice for 30 min. 
Lysates were centrifuged at 4 °C, 13,000 g for 15 min and the supernatant was subjected to 
immunoprecipitation using primary antibodies or IgG control and protein A agarose beads 
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(Cell Signaling Technology, Beverly, MA, USA). Precipitated immunocomplexes were 
washed five times with washing buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM 
EDTA, and 1% Triton X-100) and subjected to immunoblotting analysis. The following 
antibodies were used: anti-SRC-1 (Cell Signaling Technology, 128E7, #2191); anti-
Glucocorticoid Receptor (Cell Signaling Technology, D8H2, #3660); anti-p300 (Cell 
Signaling Technology, C-20, sc-585); anti-actin (Sigma, A3853).
Dual luciferase reporter assay
The promoter of human CXCR4 (NM_001008540.1) was cloned into pGL4.10[luc2] 
(Promega, #E6651) between the Xho1 and HindIII restriction sites, generating pGL4.10-
PCXCR4[luc2]. Glucocorticoid response element (GRE) deletion, generating pGL4.10-
PCXCR4(ΔGRE)[luc2] was performed by deletion PCR amplification using sense primer 5′-
CTGTTTGCAAACGTACAAGTGCAGAGAAGGCGTGC-3′ and anti-sense primer 5′-
CCTTCTCTGCACTTGTACGTTTGCAAACAGCGTGC-3′. pGL4.10-PCXCR4[luc2] or 
pGL4.10-PCXCR4(ΔGRE)[luc2] was co-transfected with pGL4.75[hRluc/CMV] (Promega, 
#E6931) into human CB CD34+ cells using nucleofector (Lonza). After 24 hours, vehicle or 
Flonase was added and the cells were incubated for 16 hours. Promoter activity was 
examined using the Promega Dual-Luciferase Reporter Assay System (#E1910), following 
the manufacturer’s instructions. Briefly, cells were washed with PBS and lysed in passive 
lysis buffer for 15 min. 100 μL of LAR II substrate was predispensed into each well of white 
microtiter plates. 20 μL of cell lysate was carefully transferred into the firefly luciferase 
assay reagent and mixed by pipetting 3 times. After a 5-min reaction, the plate was placed in 
the luminometer for reading of the luminescent signal generated by Firefly luciferase. 100 
μL of Stop & Glo Reagent was dispensed into each sample and vortexed briefly to mix. A 
second reading was initiated for the luminescent signal generated by Renilla luciferase. The 
relative promoter activity was calculated as Readout[luc2]/Readout[hRluc].
Statistical analysis
Data are shown as mean values ± standard deviation (SD), unless stated to show standard 
error of the mean (SEM). Statistical analysis was performed using Microsoft Excel and 
GraphPad Prism 5.0. Two-tailed Student’s t-tests were performed for statistical analysis 
between two groups. One-way or two-way analysis of variance (ANOVA) was used to 
compare the difference in means between more than two groups where indicated. P-value 
less than 0.05 was considered as statistically significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Editorial summary
Glucocorticoid treatment of human cord blood hematopoietic stem cells increases 
expression of the receptor CXCR4 by chromatin remodeling, thereby enhancing 
hematopoietic stem cell homing and engraftment.
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Figure 1. Glucocorticoids increase surface expression of CXCR4 and promote SDF-1/CXCR4 
axis mediated chemotaxis, homing and long term engraftment of human hematopoietic stem and 
progenitor cells
(a) Mean fluorescence intensity (MFI) of surface CXCR4 of human cord blood (CB) CD34+ 
cells after treatment of the cells for 16 hours with compounds from a nuclear receptor ligand 
library. The concentration of all compounds used in this study was 1 μM unless otherwise 
stated.
(b) Quantification of mean fluorescence intensity (MFI) of surface CXCR4 of human CB 
CD34+ cells treated with vehicle, Flonase, dexamethasone (Dex), cortisol or 
methylprednisolone (Medrol). Data pooled from three independent experiments are shown 
(n=9 cultures per group, one-way ANOVA).
(c) Histogram of surface CXCR4 expression of human CB CD34+ cells treated with vehicle 
or Flonase. Representative histograms from three independent experiments are shown.
(d) Confocal imaging analysis of surface CXCR4 expression of human CB CD34+ cells 
treated with vehicle or Flonase. FITC (green) indicates CXCR4 expression; DAPI (blue) 
labels the cell nucleus. Representative images from two independent experiments are shown 
(the inset shows the amplified part of the image). Scale bar: 20 μm.
(e) Quantification of mean fluorescence intensity (MFI) of surface CXCR4 of human CB 
HSCs (CD34+CD38−CD45RA−CD90+CD49f+) treated with vehicle or Flonase (n=9 
cultures per group). Data pooled from three independent experiments are shown.
(f) Migration of human CB CD34+ cells towards human recombinant SDF-1α, as quantified 
by flow cytometry. The cells were cultured in the presence of vehicle or Flonase for 16 hours 
and then allowed to migrate towards the indicated concentrations of SDF-1α for 4 hours. 
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Data pooled from two independent experiments are shown (n=6 cultures per group, two-way 
ANOVA).
(g) Migration of human phenotypic HSCs in CB CD34+ cells towards human recombinant 
SDF-1α (50 ng/mL), as quantified by flow cytometry. The migration percentage of HSCs 
was calculated as the HSC (CD34+CD38−CD45RA−CD90+CD49f+) frequency among 
migrated CD34+ cells. Data pooled from two independent experiments are shown (n=6 
cultures per group).
(h) Migration of vehicle or Flonase treated human CB CD34+ cells in the presence of the 
CXCR4 antagonist, AMD3100 (5 μg/mL), as quantified by flow cytometry. Data pooled 
from three independent experiments are shown (n=9 cultures per group, one-way ANOVA).
(i) The percentage of human CD45+ cells in the bone marrow of NSG mice 24 h after 
transplantion with 500,000 CB CD34+ cells that had been treated with vehicle or Flonase. 
CD34+ cells from four cord blood samples (CB#1-4) were tested. (n=6 mice per group).
(j) The percentage of human CD45+ cells in peripheral blood (PB) and BM of NSG mice at 
the indicated time points after transplantation with 10,000 CB CD34+ cells that had been 
treated with vehicle or Flonase. (n=4 mice in vehicle group and n=5 mice in Flonase group).
(k) The percentage of human CD33+ myeloid cells in BM of NSG mice 4 months after 
transplantation with 10,000 CB CD34+ cells that had been treated with vehicle or Flonase 
(n=4 mice in vehicle group and n=5 mice in Flonase group).
(l,m) The frequency of human SRCs in CB CD34+ cells treated with vehicle or Flonase, as 
determined by transplantations of graded doses of treated cells into NSG mice and 
determination of human CD45+ cell chimerism 3 months after transplantation (n=4–5 mice 
per group, see Supplementary Table 2). (l) Poisson statistical analysis of data from 
Supplementary Table 2. Shapes (circle or triangle in the plot) represent the percentage of 
negative mice for each dose of cells. The inverted triangles indicate that all tested mice were 
positive in this group. Solid lines indicate the best-fit linear model for each data set. Group 
A (black line) indicates vehicle group, Group B (red line) indicates Flonase group. Dotted 
lines represent 95% confidence intervals. (m) HSC frequencies (line in the box) and 95% 
confidence intervals (box) presented as the number of SRCs in 1×106 CD34+ cells.
(n) Human CD45+ cell chimerism in the PB and BM of secondary recipient NSG mice, 
which had been transplanted with 5×106 bone marrow cells from primary recipient NSG 
mice (n=5 mice per group). Data are shown as dot plots (mean±s.e.m.) in j, k, n, or as box-
and-whisker plots (the lines indicate median values, the whiskers indicate minimum and 
maximum values, the boxes indicate interquartile range) in b and e–h. *p<0.05. **p<0.01. 
***p<0.001.
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Figure 2. Glucocorticoids enhance H4K5 and H4K16 acetylation associated with the CXCR4 
promoter, facilitate expression of CXCR4 and promote homing of human CB CD34+ cells
(a) CXCR4 mRNA levels in Flonase, cortisol or Dex treated human CB CD34+ cells, 
relative to vehicle-treated cells, as assessed by quantitative realtime-PCR. Data pooled from 
three independent experiments are shown (n=9 replicates per group, one-way ANOVA).
(b,c) Total CXCR4 protein levels in Flonase, cortisol or Dex treated human CB CD34+ cells, 
relative to vehicle-treated cells, as assessed by western blotting. A representative blot is 
shown in b, and quantification of CXCR4 protein levels from three independent western blot 
assays is shown in c (n=3 experiments, one-way ANOVA). Actin was used as a loading 
control. Uncropped images of blots are shown in Supplementary Figure 4a.
(d) GR levels at the CXCR4 promoter in vehicle or Flonase treated human CB CD34+ cells, 
as assessed by a chromatin immunoprecipitation (ChIP) assay. Data pooled from two 
independent experiments are shown (n=6 replicates per group).
(e) Promoter activities of the full length CXCR4 promoter (PCXCR4) and a glucocorticoid 
response element (GRE) defective form of the CXCR4 promoter (PCXCR4 (ΔGRE)) treated by 
vehicle or Flonase, as determined by a dual-luciferase reporter assay system. The relative 
luciferase activity of vehicle treated full length CXCR4 promoter group was set to 1 (n=3 
replicates per group, one-way ANOVA). Representative data from three independent 
experiments are shown.
(f,g) Acetylated H4K5 (H4K5ac, f) and H4K16 (H4K16ac, g) levels at the CXCR4 promoter 
in vehicle or Flonase treated human CB CD34+ cells, as assessed by a ChIP assay. Data 
pooled from two independent experiments are shown (n=8 replicates per group).
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(h) Levels of SRC1 and p300 that are co-immunoprecipitated with receptor GR in vehicle or 
Flonase treated human CB CD34+ cells. Extracts of treated cells were immunoprecipitated 
with anti-GR antibody and the resulting precipitates were analyzed by western blot. GR and 
actin in the whole cell lysate (WCL) serve loading controls. Representative data from three 
independent experiments are shown. Uncropped images of blots are shown in 
Supplementary Figure 4b.
(i) Mean fluorescence intensity of surface CXCR4 in vehicle, c646 (30 μM), Flonase (10 
nM), Flonase+c646, cortisol (1μM), cortisol+c646, Dex (100 nM), or Dex+c646 treated 
human CB CD34+ cells, as assessed by flow cytometry. Data pooled from two independent 
experiments are shown (n=6 cultures per group, one-way ANOVA).
(j) The percentage of human CD45+ cells in the bone marrow of NSG mice 24 h after 
transplantion with 500,000 CB CD34+ cells that had been treated with vehicle, c646 (30 
μM), Flonase (10 nM) or Flonase+c646. (n=5 mice per group, one-way ANOVA). Data are 
shown as dot plots (mean±s.e.m.) in j, or as box-and-whisker plots (the lines indicate median 
values, the whiskers indicate minimum and maximum values, the boxes indicate 
interquartile range) in d, f, g and i. NS, not significant. **p<0.01. ***p<0.001.
(k) Model for the role of glucocorticoids in regulating CXCR4 expression in human HSC/
HPCs. Glucocorticoid binding to GR in the cytoplasm results in GR activation, translocation 
to the nucleus and dimerization. The GR homodimer recognizes and binds to a GRE in 
CXCR4 promoter. Activated GR recruits SRC1, p300 and other co-factors with histone 
acetyltransferase activity to enhance acetylation of histone 4 on lysine 5 and lysine 16. 
Acetylation of histone 4 facilitates chromatin remodeling and promotes expression of 
CXCR4, and thus enhances HSC/HPC homing and engraftment.
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